Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis

Fig. 2

IPF-MSCs displayed increased cellular senescence. a Western blotting analysis of the expression of p21 and p16 in control-MSCs and IPF-MSCs. b Cell growth curves demonstrate the lower proliferative ability of IPF-MSCs compared with control-MSCs. c BrdU assay shows a decreased absorbance at 450 nm of IPF-MSCs compared with control-MSCs. d Representative images of SA-β-gal staining and quantitative analysis of SA-β-gal-positive cells in control-MSCs and IPF-MSCs. Scale bar = 200 μm. e Immunostaining of the proliferation marker Ki67 and quantitative analysis of Ki67-positive cells in control-MSCs and IPF-MSCs. Scale bar = 100 μm. f Immunostaining of the DNA damage marker γH2AX and quantitative analysis of γH2AX-positive cells in control-MSCs and IPF-MSCs. Scale bar = 200 μm. All data were obtained from at least three independent experiments and each error bar represents the mean ± SEM. **p < 0.01; ***p < 0.001

Back to article page